Acquisition of a Significant Stake in Felix by Advent
In a notable deal, Arthur Cox LLP, a leading Irish law firm, has advised Advent International, a prominent global private equity investor, on the acquisition of a significant minority stake in Felix Pharmaceuticals Pvt Ltd, a leading global Gx animal pharma player.
The deal saw Advent International bolster its presence in the animal pharmaceuticals sector. The key team members from Arthur Cox LLP involved in the advisory role included tax partner David Kilty and senior associate Nicola Cavey.
In the Corporate and M&A sector, the team from Arthur Cox LLP included Tim Gleeson, Daire Cassidy, Glyn McCormack, and Sondos Siiddiqi. Colin Kavanagh was part of the team in the Life Sciences sector. Simon Breen and Robert Byrne were part of the team in the Competition and Regulated Markets sector.
While Advent International's internal team members advising on this deal were not explicitly listed, the firm's broader support ecosystem often involves Operating Partners and Operations Advisors such as Frank Roe (Operating Partner) and Seth Farbman (Marketing Operations Advisor). These individuals provide operational and marketing expertise, respectively, but were not explicitly listed as deal advisors for this transaction.
Felix Pharmaceuticals was advised by JSA, but the key Advent advisors named in public disclosures were from Arthur Cox LLP’s tax team.
Michael Coyle led the team from Arthur Cox LLP in advising Advent International on this acquisition.
For more information about Advent International and its investments, please visit their website.
- Advent International, a renowned global private equity investor, strengthened its presence in the animal pharmaceuticals sector through a notable acquisition facilitated by tax partner David Kilty and senior associate Nicola Cavey from Arthur Cox LLP, a leading Irish law firm in the field of finance.
- The finance deal involved private equity, with Michael Coyle from Arthur Cox LLP's tax team providing key advice to Advent International on the acquisition of a significant minority stake in Felix Pharmaceuticals Pvt Ltd.
